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Abstract
Background: Cryptosporidium is a protozoan parasite of humans and other animals worldwide and is one of the
greatest contributors to human diarrhoeal illness. Transmission can occur indirectly via contaminated food or water,
or directly via contact with animals or other infected people. Risk exposures are often identified from outbreak
investigations, but a subset of cases remains unexplained, and sources for sporadic disease and pathways to
infection are still unclear.
Given the few systematic syntheses of reported evidence in industrialised populations, the aim of this review is to
consolidate the literature to describe exposures associated with human cryptosporidiosis in industrialised countries,
specifically including the UK, and describe any differences between outbreak-associated and sporadic disease.
Methods/design: Where relevant, methods will follow the recommendations made in the Cochrane Handbook for
Systematic Reviews of Interventions. Three steps will be used to identify the literature including electronic database
searching using PubMed, Scopus, Embase and Web of Science; reference list trawling; and an exploration of the grey
literature. Screening of results will be undertaken by two reviewers using pre-defined criteria. Studies conducted in
industrialised countries and reporting on human subjects will be included. All observational studies will be included
where they report exposures and relevant quantitative results.
Data will be extracted using a standardised form. Study quality will be assessed using the ROBINS-I tool. Data will be
summarised presenting the papers’ main findings including population under study, outcomes, and exposures, and
whether these were considered outbreak or sporadic cases. A narrative summary will also be included. Where populations
are appropriate, available data will be pooled in a meta-analysis combining the significant exposures across studies.
Discussion: This review aims to consolidate the evidence for transmission routes and exposures for Cryptosporidium in
industrialised countries, with particular reference to how these may apply to the UK. In addition, the review will seek to
describe differences between outbreak and sporadic cases. This will help to identify those most vulnerable, highlighting
pathways where interventions and public health response may be appropriate.
Systematic review registration: PROSPERO number CRD42017056589.
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Background
Cryptosporidium is a protozoan parasite which can infect
humans and other animals, and the most prevalent species
identified in humans are Cryptosporidium parvum and
Cryptosporidium hominis [1, 2]. Cryptosporidium is distrib-
uted worldwide and is suspected to be one of the greatest
contributors to human diarrhoeal illness [3]. Cryptosporid-
ium is reported in 1–3% of immunocompetent patients
with diarrhoea in industrialised countries and 7–20% in de-
veloping countries [4–8]. The dissimilarities are probably
driven by variation in exposure due to sanitation, infra-
structure, and housing and health factors such as acquired
immunity and nutrition. The highest prevalence is observed
among children under 5 years old, in particular the under
twos [3, 9]. The parasite has a complex life cycle and char-
acteristics which favour the faecal-oral transmission route,
which may facilitate outbreaks via person-to-person (C.
hominis and C. parvum) or animal-to-person (C. parvum),
as well as indirect transmission through ingestion of water
and food contaminated with infectious oocysts [10].
Reported risk exposures for both C. parvum and C. homi-
nis often overlap and include consumption of contaminated
drinking water [11–15] and exposure to recreational waters
[16–18] and food-related outbreaks (likely contaminated
via water or by food handlers) [19–22].
C. parvum is frequently associated with exposure to farm
animals [23, 24] due to its zoonotic nature and C. hominis,
more anthropo-zoonotic, with person-to-person spread
[25–28] and foreign travel [29]. Risk factors and associated
exposures are often hypothesised/identified from outbreak
investigations; however, outbreaks may only represent a
small proportion of cases. Estimates in the United Kingdom
(UK) suggest, of all cases reported to national surveillance
in England & Wales, < 10% are likely to be linked to an
identified outbreak [30]. However, the accuracy of the
case numbers captured by surveillance may be imprecise
[31, 32]. As a consequence, pathways may be under-
reported and we cannot be certain that transmission
routes for sporadic disease are the same as those which
drive outbreaks [33]. Despite case-control studies which
have investigated differences in risk for endemic and out-
break disease [34, 35], sources for sporadic disease and
pathways to infection are still unclear and a substantial
subset of reported cases remain unexplained.
Previous reviews
A search of PubMed and the Cochrane Library revealed
five previous systematic reviews which have synthesised
evidence on risk factors for infection, all published be-
tween 2006 and 2016.
Two reports dealt with only immunocompromised
populations: a review of Cryptosporidium prevalence in
HIV/AIDS patients [36] and another assessing the treat-
ment in immunocompromised patients [37]. A 2006
global review by Gualberto and Heller of drinking water
sources found that unboiled water was associated with
an increased risk of endemic cryptosporidiosis [38].
Another paper looked at seasonal patterns of five gastro-
intestinal pathogens together, including Cryptosporid-
ium, in the Organisation for Economic Co-operation
and Development (OECD) countries [39]. The paper
hypothesised that environmental factors, e.g. land use,
rainfall, temperature, and host characteristics, e.g. social
contact, travel, and animal proximity, were drivers for
seasonal patterns of cryptosporidiosis, and this was fur-
ther buttressed by the existence of comparable evidence
from New Zealand for other enteric pathogens [40].
However, these reviews were unable to report results by
Cryptosporidium species, which may impact on risk fac-
tors, or investigate separately sporadic and outbreak-
related cases for any variation in associations.
Given the absence of any systematic synthesis of re-
ported evidence in the UK, and the few reviews in the
rest of the industrialised countries, the aim of this review
is to search the literature, including unpublished work,
and describe the purported exposures associated with in-
fection with Cryptosporidium in industrialised countries,
specifically including the UK. In addition, there may be
scope for a meta-analysis to support assessment of the
available evidence and to explore differences that may
exist in exposures or associations between sporadic and
outbreak-related cases.
Research question
In industrialised populations, what exposures are associated
with human infection with Cryptosporidium and are these
different for outbreak-associated and sporadic disease?
Methods
To improve the transparency and completeness of the
protocol, a copy of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses for Protocols
2015 (PRISMA-P 2015) [41] checklist can be found in
Additional file 1. This protocol is written following this
checklist and guidance.
Population
The review will include human populations only.
To avoid missing papers that may be useful to this re-
view, a decision was made not to exclude key at-risk
groups, where known, such as HIV/AIDS patients. The
wealth of literature available indicates that these are
well-studied groups and may act as good sentinels for
the identification of transmission risks or pathways for
immunocompetent populations. At the data collection
and analysis stages, high-risk or highly susceptible popu-
lations, where known, can be separated for a more nu-
anced interpretation.
McKerr et al. Systematic Reviews  (2018) 7:70 Page 2 of 8
Searches will be restricted to reports from industrialised
countries given that the literature suggests that transmis-
sion pathways and exposures, as well as susceptibility of
populations, are different between these and countries
with less infrastructure [42]. An industrialised country will
be defined using OECD category of countries based on
membership (Table 1) [43]. Where studies report results
from a mix of industrialised and non-industrialised coun-
tries, and it is not possible to disentangle outcomes and
exposures, the study will be excluded.
Exposure
All exposures, including food, water, animal, environ-
mental, and human, will be considered for inclusion.
Outcome
Primary outcomes will include identifying exposures associ-
ated with Cryptosporidium infection and/or disease among
both sporadic disease and outbreak-related cases. Out-
comes among exposed populations will be compared to
those in unexposed populations, where the study design al-
lows. We are also interested in capturing molecular detail
such as species where possible, as risk factors and expo-
sures may vary.
Inclusion/exclusion criteria (Table 2)
Only studies conducted in industrialised countries (as
previously described) and reporting on human subjects
will be included. All observational studies will be in-
cluded where they report risk factors and relevant quan-
titative results. To allow us to capture the most relevant
and robust information on risk factors at a population
level, individual case reports will be excluded.
Where the information is clearly communicated, we
will exclude information describing cases who acquired
their infection in a non-industrialised country and there
is no further follow-up, for example, reporting on sec-
ondary spread. Where we cannot accurately determine
country of infection, these will be excluded.
To capture any changes in incidence and factors associ-
ated with Cryptosporidium over time, there will be no
limitation on publication period. We are also interested in
capturing molecular detail, such as species, where pos-
sible, as risk factors and exposures for these may vary and
this may be pertinent for comparisons of pathways and of
value to the knowledge of zoonotic transmission routes.
There are no restrictions on language, provided the
abstract can be made available in English for the first
round of screening.
Search strategy and terms
Where relevant, methods will follow the recommenda-
tions made in the “Cochrane Handbook for Systematic
Reviews of Interventions” [44].
The search strategy proposed comprises three ap-
proaches, designed to collect as much relevant literature
as possible from both peer-reviewed and grey sources.
The choice of databases was following advice from a
University of Liverpool Medicine and Dentistry Liaison
Librarian, as those deemed to be most relevant to the re-
search question and likely to yield the highest number of
relevant papers.
Step one—peer-reviewed literature
One reviewer (CMCK) will conduct electronic searches
in the following databases of published literature consid-
ered most likely to yield the relevant papers:
Table 1 Current membership—OECD
Australia Japan
Austria Korea
Belgium Latvia
Canada Luxembourg
Chile Mexico
Czech Republic Netherlands
Denmark New Zealand
Estonia Norway
Finland Poland
France Portugal
Germany Slovak Republic
Greece Slovenia
Hungary Spain
Iceland Sweden
Ireland Switzerland
Israël Turkey
Italy United Kingdom
United States
Table 2 Criteria for inclusion in the search
Inclusion criteria Exclusion criteria
Any language—abstract
(if available) in English
Cases known/defined as travel-
related/acquired in non-
industrialised country
Publication period—any Individual case reports
Human cases
All Cryptosporidium sp. including
mixed
Industrialised countries
Known immunocompromised
groups where risk factors are
reported
Known outbreaks
McKerr et al. Systematic Reviews  (2018) 7:70 Page 3 of 8
 PubMed
 Web of Science
 Scopus
 Embase
The search terms were developed initially for PubMed
and piloted in an iterative process ahead of commencing
the review to ensure they successfully captured relevant
papers. Where possible, terms were exploded to broaden
the search. In the review, terms will be adapted as per
the functionality of each database.
A more complete documented approach to develop-
ing the choices and finalising search terms is available
on request.
Terms include the following categories:
 Organism terms: e.g. crypto*, Cryptosporidium,
cryptosporidiosis
 Population term: e.g. “human”, patients, population,
 Transmission terms: e.g. transmission, risk factor,
exposure, sporadic, infection, outbreak(s)
 Outcome terms: e.g. multivariate analysis, odds
ratio, risk*, relative risk
Additional file 2 is an example of final search terms
used for PubMed.
Search terms will be sought within the title, abstract,
and keywords of the documents contained in each data-
base. Filters within the three databases will be applied if
required to restrict the results as appropriate according
to inclusion criteria.
The publications captured using the final agreed search
terms will be exported into reference managing software
(Mendeley) and duplicates removed. The remaining publi-
cation titles will then be screened for relevance by two re-
viewers (CMCK and AW), using the inclusion and
exclusion criteria.
Step two—hand-searching in papers
Reviewers (CMCK and AW) will search reference lists to
identify any further literature or relevant publications
not previously captured in the other strategies. The ab-
stracts of any references considered potentially relevant
will be sought and screened for inclusion using the in-
clusion and exclusion criteria.
Step three—accessing grey literature
One reviewer (CMCK) will access grey literature rele-
vant to the review question using published online re-
sources which may include bulletins and reports from
relevant agencies, conference proceedings, and other
relevant published outputs.
A search of Google Scholar (and any other relevant
agencies’ sites, e.g. WHO) will be undertaken by entering
the term ‘cryptosporidium’ with ‘risk factors’, ‘outbreak(s)
’, ‘sporadic’, ‘endemic’, and/or ‘transmission’ into the appli-
cation and reviewing the first 100 results for relevance.
Using the same search terms and inclusion criteria, the
same reviewer will carry out an additional search for un-
published theses work in the ProQuest database.
Abstracts (or relevant variations thereof) will be shared
with the second reviewer (AW). Following agreement on
inclusion, the work will be reviewed as per protocol.
To refine and clarify the inclusion criteria and search
terms and ensure that the criteria can be applied consist-
ently by all reviewers, the selection process will be
piloted by applying criteria to a sample of papers.
Abstract and paper selection
Following title selection, abstracts of the final included
publications will be screened independently by two mem-
bers of the review team (CMCK and AW) to ensure
consistency in the application of the inclusion and exclu-
sion criteria. Any discrepancies will be discussed and re-
examined until an agreement is reached. A third reviewer
is available for irreconcilable opinions on inclusion.
The full texts for all included works will be retrieved
via the online library where possible and, if required,
with the help of the University Liaison Librarian or by
contacting authors. All full-text studies will be screened
independently by the same reviewers (CMCK and AW)
to ensure that they conform to the inclusion and exclu-
sion criteria and discrepancies tackled as before.
Full-text papers which appear in a language other than
English will be shared with colleagues in the Health Protec-
tion Research Unit (HPRU) and wider university teams for
assistance with translation. An online translation tool (Goo-
gle translate) will be used for initial screening where needed
and where electronic papers are available for input.
Searching will cease when no further relevant and/or
not previously identified work is being discovered.
Data collection
A standardised data collection form will be developed in
Covidence software. Each reviewer will be able to input
data and update this as they each extract data from the
papers. A minimum dataset of information from each
paper will be extracted and recorded in duplicate, by
each reviewer and, where information is available, will
include variables outlined in Table 3.
Studies will be allocated a unique identifier (automat-
ically generated) and will be categorised according to the
following groups:
 Included studies—studies that meet the eligibility
criteria and are included in the review
 Excluded studies—studies that do not meet the
eligibility criteria and are excluded from the review
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 Studies awaiting classification—relevant studies that
have been identified but cannot be assessed for
inclusion until additional data or information are
obtained
 Ongoing studies—studies that are ongoing and meet
(or appear to meet thus far) the eligibility criteria
Disagreements will be discussed and, if required, rely
on the input of a third reviewer as previously described.
Assessing risk of bias
The ROBINS-I tool (Risk Of Bias In Non-randomized
Studies - of Interventions) will be used as the framework
for assessing quality of the studies. This instrument is well
piloted and is specific to non-randomised study types [45].
The instrument provides an overall judgement on risk of
bias using signalling questions across seven domains includ-
ing bias, confounding, and missing data. Following assess-
ment, each reviewer will label a study as ‘low’, ‘moderate’,
‘serious’, or ‘at critical’ risk of bias.
Strategy for data synthesis
Search results and numbers of titles selected will be pre-
sented in the PRISMA 2009 flowchart [46].
In order to accurately report on the content of papers
and to explore relationships between disease outcomes
and risk factors, data will be summarised in a table pre-
senting the main findings of each paper individually, in-
cluding population under study, outcomes (infection with
Cryptosporidium sp.), exposures, and general results
(rates, prevalence, number of cases, odds, relative risks). A
narrative summary of the characteristics and quality of the
papers will also be included, alongside, and in the context
of the strength of evidence results from ROBINS-I.
Meta-analysis
A certain level of heterogeneity is expected between
studies which may include outcomes measured, popula-
tion groups, type of study, and measures of association.
Following these results, and a discussion about compar-
ability of studies reported, a decision will be made re-
garding moving forward with a meta-analysis.
Where the populations are appropriate, and study qual-
ity allows, data will be pooled in a meta-analysis combin-
ing the significant exposures, and categories, across
studies and presented as a summary of effects in their in-
dividual groupings, for example, ORs or RRs. Forest plots
will be created for each exposure category (where paper
numbers are high enough to retain validity) and examined
to identify heterogeneity. Odds or risk of exposure among
cases of Cryptosporidium will be presented according to
the study design and outcome measured.
The summary measure and I2 statistic will be used to
assess heterogeneity in the studies and will inform the
use of meta-analysis techniques and the choice of a fixed
or random effects model. Values of 30 to 60%, 50 to 90%
and 75 to 100% will be used to denote moderate, sub-
stantial, and considerable levels of heterogeneity accord-
ing to the Cochrane Handbook for Systematic Reviews
of Interventions [44].
Data analyses will be carried out using RevMan, MS
Access and Stata v12.0.
Data analysis plan
The data analysis will include a description of the cases
and putative risk factors/exposures in each study, includ-
ing the overall proportion of studies which report each
exposure and the number of times a transmission path-
way or risk factor is associated with illness.
Where possible, analyses of subgroup data may include:
 Outbreak vs non-outbreak disease
 Urban vs rural residence/populations
 Region of world
 Cryptosporidium species/genotype (e.g. C. parvum
and C. hominis)
 Age groups of cases/non-cases
Table 3 Minimum data set of information extracted from
included papers
Bibliographic detail Study detail
Name of reviewer Study design
Date of extraction Number of cases
reported
Publication type Age/sex cases/
participants
Country of origin/language Case definition (and any
known co-infections)
Study title Definition of exposure(s)
Names of authors Definition of activities
Journal/source reference Species identified
Year published Incubation period
Exposure window(s)
Study outcomes General methodological
Number (%) exposed among groups Confounders
Types of exposures Likely biases
Comparator(s) (well controls, other
infection)
Selection and recruitment methods
Availability of appropriate controls
(from the same source population as
the cases)
Interview methods
Effect measures (type and result)
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 Study design (such as cross-sectional, prevalence
studies with risk factors, case-control, cohort, and
other observational study designs, outbreak investi-
gations, or surveillance analyses with risk factor
information)
Aggregated study data by subgroup will be reported
according to data type (e.g. mean and SD and percent-
ages, ratios) and outcome measures (e.g. incidence, odds
ratios, and relative risks). Studies will be further grouped
by outcome measurement for consistency; studies
reporting odds ratios will be aggregated separately to
those reporting relative risk, for example. Exposures will
be defined as per the paper under review, but where
possible, they will be grouped into categories to allow
for meaningful exposure group analyses. Categories are
likely to include environmental exposures, water, animal
exposures, exposure to a case, etc., and may also, where
possible, include settings such as home, hospital, or nur-
sery. Where data and number of papers allow these will
be sub-grouped as much as possible.
Where data are missing or not reported in disaggre-
gate form, the authors may be contacted in order to as-
sist with further analyses. If the data allow, a more
granular grouping of the studies may be undertaken to
accurately address the research question.
Interpretation of findings
Given that we have not included any element of study
design as part of the selection criteria for inclusion,
interpretation of findings will begin with a description
of the publication bias funnel plots where numbers of
papers are sufficient. Discussions will include an ex-
ploration of all the strengths and weaknesses of the
studies and a summary of the quality of evidence,
using the Grading of Recommendations, Assessments,
Development and Evaluation approach [47]. Most of
the initial studies will likely be classed a priori as
‘low’ due to being observational in nature but may be
upgraded after assessment of various domains of the
tool, including bias, effect size, and precision. Papers
will then be assigned a final grade for the quality of
evidence as ‘high’, ‘moderate’, ‘low’, or ‘very low’ for all
the critically important outcomes. Results will be re-
ported using summary tables.
Interpretations of measures of effect may be stratified
by study quality, and aggregated analyses of measures of
effect will be assessed in the context of the populations
under study.
Dissemination
The protocol and the report will be prepared for peer-
review publication.
The review will form part of a larger project submitted
in partial fulfilment of a Doctor of Philosophy degree at
the University of Liverpool.
Where appropriate, data may be presented as confer-
ence proceedings.
Discussion
Many of the putative risk factors for cryptosporidiosis can
have high exposure proportions and cases often report
multiple risk factors, so well-designed studies are key in
trying to elucidate clear pathways for transmission. More
accurate understanding of the drivers behind continued
apparent sporadic cryptosporidiosis has implications for
public health intervention, control, and targeted treat-
ment. This systematic review aims to describe the epi-
demiology and transmission of Cryptosporidium infection
in industrialised countries, with particular reference to
how this may apply to the UK. In addition, the review will
seek to describe differences between outbreak and spor-
adic cases, investigating changes in prevalence and pat-
terns among species and subtypes over time, and explore
mechanisms for transmission of disease.
The results of this review will help support current
knowledge and add to the evidence base on transmission
pathways and risks for cryptosporidiosis, identifying
those vulnerable and highlighting pathways where inter-
ventions may be of use.
The review will also help inform the development and
direction of an analytical study as part of a PhD project.
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